Display options
Cite
Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22(1):22-31doi: 10.2165/00003088-199222010-00003.
Meredith, P. A., & Elliott, H. L. (1992). Clinical pharmacokinetics of amlodipine. Clinical pharmacokinetics, 22(1), 22-31. https://doi.org/10.2165/00003088-199222010-00003
Meredith, P A, and Elliott, H L. "Clinical pharmacokinetics of amlodipine." Clinical pharmacokinetics vol. 22,1 (1992): 22-31. doi: https://doi.org/10.2165/00003088-199222010-00003
Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992 Jan;22(1):22-31. doi: 10.2165/00003088-199222010-00003. PMID: 1532771.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Clin Pharmacokinet. 1992 Jan;22(1):22-31. doi: 10.2165/00003088-199222010-00003.

Clinical pharmacokinetics of amlodipine.

Clinical pharmacokinetics

P A Meredith, H L Elliott

Affiliations

  1. University Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow.

PMID: 1532771 DOI: 10.2165/00003088-199222010-00003

Abstract

Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics which appear to be attributable to a high degree of ionisation. Following oral administration, bioavailability is 60 to 65% and plasma concentrations rise gradually to peak 6 to 8h after administration. Amlodipine is extensively metabolised in the liver (but there is no significant presystemic or first-pass metabolism) and is slowly cleared with a terminal elimination half-life of 40 to 50h. Volume of distribution is large (21 L/kg) and there is a high degree of protein binding (98%). There is some evidence that age, severe hepatic impairment and severe renal impairment influence the pharmacokinetic profile leading to higher plasma concentrations and longer half-lives. There is no evidence of pharmacokinetic drug interactions. Amlodipine shows linear dose-related pharmacokinetic characteristics and, at steady-state, there are relatively small fluctuations in plasma concentrations across a dosage interval. Thus, although structurally related to other dihydropyridine derivatives, amlodipine displays significantly different pharmacokinetic characteristics and is suitable for administration in a single daily dose.

Cited by

References

  1. Br J Clin Pharmacol. 1986 Jul;22(1):21-5 - PubMed
  2. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S67-71 - PubMed
  3. Clin Pharmacol Ther. 1990 Jul;48(1):76-86 - PubMed
  4. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S94-7 - PubMed
  5. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S60-3 - PubMed
  6. Xenobiotica. 1988 Feb;18(2):245-54 - PubMed
  7. J Clin Pharmacol. 1988 Nov;28(11):990-4 - PubMed
  8. Mol Pharmacol. 1989 Oct;36(4):634-40 - PubMed
  9. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S98-102 - PubMed
  10. Am J Hypertens. 1989 Mar;2(3 Pt 1):154-7 - PubMed
  11. Am Heart J. 1989 Nov;118(5 Pt 2):1100-3 - PubMed
  12. J Intern Med. 1989 Feb;225(2):101-5 - PubMed
  13. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S55-9 - PubMed
  14. J Hum Hypertens. 1988 Aug;2(2):127-32 - PubMed
  15. Br J Clin Pharmacol. 1987 Dec;24(6):713-9 - PubMed
  16. J Cardiovasc Pharmacol. 1993;22 Suppl A:S9-12 - PubMed
  17. J Cardiovasc Pharmacol. 1988 Jul;12(1):1-5 - PubMed
  18. J Chromatogr. 1987 Sep 4;420(1):178-83 - PubMed
  19. Arzneimittelforschung. 1989 Jul;39(7):799-801 - PubMed
  20. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S79-84 - PubMed
  21. Clin Pharmacokinet. 1987 Jan;12(1):12-29 - PubMed
  22. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S64-6 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources